A Study of Tirzepatide in Overweight and Very Overweight Participants

NCT04311411 · Completed

Last updated 2026-05-28

This study tests whether tirzepatide, compared to a placebo, reduces calorie intake in adults who are overweight or obese over a 3-week period.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 114 people

Who can join Ages 18–65 · all sexes

Timeline Started 2020-08 · est. completion 2022-12

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT04311411 ↗

Description as written by the study sponsor.

The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC.
Placebo Drug

Administered SC.
Liraglutide Drug

Administered SC.

Main thing measured	Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04311411 ↗